Epcoritamab monotherapy in patients with relapsed or refractory follicular lymphoma (EPCORE NHL-1): a phase 2 cohort of a single-arm, multicentre study

滤泡性淋巴瘤 医学 耐火材料(行星科学) 队列 卵泡期 肿瘤科 内科学 淋巴瘤 美罗华 队列研究 天体生物学 物理
作者
Kim Linton,Umberto Vitolo,Wojciech J. Jurczak,Pieternella Johanna Lugtenburg,Emmanuel Gyan,Anna Maria Sureda,Jacob Haaber Christensen,Brian T. Hess,Hervé Tilly,Raúl Córdoba,David John Lewis,Craig Y. Okada,Martin Hutchings,Michael Roost Clausen,Juan‐Manuel Sancho,Tara Cochrane,Sirpa Leppä,Martine E.D. Chamuleau,Diana Gernhardt,Işıl Altıntaş
出处
期刊:The Lancet Haematology [Elsevier BV]
卷期号:11 (8): e593-e605 被引量:206
标识
DOI:10.1016/s2352-3026(24)00166-2
摘要

BACKGROUND: A standard of care and optimal duration of therapy have not been established for patients with multiply relapsed or refractory follicular lymphoma. The aim of this study was to evaluate epcoritamab, a novel CD3 × CD20 bispecific antibody, in the third-line and later setting of follicular lymphoma. METHODS: follicular lymphoma (grade 1-3A), an Eastern Cooperative Oncology Group performance status of up to 2, and had received at least two previous lines of therapy (including an anti-CD20 monoclonal antibody and an alkylating agent or lenalidomide). Patients were treated with subcutaneous epcoritamab 48 mg in 28-day cycles: weekly in cycles 1-3, biweekly in cycles 4-9, and every 4 weeks until disease progression or unacceptable toxicity. To mitigate the risk and severity of cytokine release syndrome, in the pivotal cohort, cycle 1 consisted of a step-up dosing regimen of a 0·16-mg priming dose on day 1 and a 0·80-mg intermediate dose on day 8, followed by subsequent 48-mg full doses and prophylactic prednisolone 100 mg; in the cycle 1 optimisation cohort, a second intermediate dose of 3 mg on day 15, adequate hydration, and prophylactic dexamethasone 15 mg were evaluated during cycle 1 to further reduce risk and severity of cytokine release syndrome. Primary endpoints were independently reviewed overall response rate for the pivotal cohort and the proportion of patients with grade 2 or worse and any-grade cytokine release syndrome for the cycle 1 optimisation cohort. Analyses were done in all enrolled patients who had received at least one dose of epcoritamab. This study is registered with ClinicalTrials.gov, NCT03625037, and is ongoing. FINDINGS: Between June 19, 2020, and April 21, 2023, 128 patients (median age 65 years [IQR 55-72]; 49 [38%] female and 79 [62%] male) were enrolled and treated in the pivotal cohort (median follow-up 17·4 months [IQR 9·1-20·9]). The overall response rate was 82·0% (105 of 128 patients; 95% CI 74·3-88·3), with a complete response rate of 62·5% (80 of 128; 95% CI 53·5-70·9). The most common grade 3-4 treatment-emergent adverse event was neutropenia in 32 (25%) of 128 patients. Grade 1-2 cytokine release syndrome was reported in 83 (65%) of 128 patients; grade 3 cytokine release syndrome was reported in two (2%). Immune effector cell-associated neurotoxicity syndrome was reported in eight (6%) of 128 patients (five [4%] grade 1; three [2%] grade 2). Between Oct 25, 2022, and Jan 8, 2024, 86 patients (median age 64 years [55-71]; 37 [43%] female and 49 [57%] male) were enrolled and treated in the cycle 1 optimisation cohort. The incidence of cytokine release syndrome was 49% (42 of 86 patients; eight [9%] grade 2; none of grade 3 or worse), with no reported immune effector cell-associated neurotoxicity syndrome. INTERPRETATION: Epcoritamab monotherapy showed clinically meaningful activity in patients with multiply relapsed or refractory follicular lymphoma, and had a manageable safety profile. FUNDING: Genmab and AbbVie.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Lee发布了新的文献求助10
刚刚
思源的应助被可恶地采纳,获得10
1秒前
moriaty发布了新的文献求助20
2秒前
石不评完成签到,获得积分10
3秒前
乔qiao完成签到,获得积分10
3秒前
lmy发布了新的文献求助10
3秒前
4秒前
打打的应助被未央采纳,获得10
5秒前
5秒前
diupapa发布了新的文献求助10
6秒前
JuJuB0nd完成签到,获得积分10
8秒前
8秒前
橙子发布了新的文献求助10
8秒前
8秒前
Chelsea完成签到,获得积分10
8秒前
8秒前
zcvxd发布了新的文献求助10
9秒前
9秒前
molin发布了新的文献求助10
9秒前
Maestro_S的应助被李瑞程采纳,获得10
10秒前
忧郁雨竹发布了新的文献求助100
11秒前
一颗苹果的应助被牧百川采纳,获得10
11秒前
绮娜完成签到,获得积分10
11秒前
12秒前
13秒前
Ava的应助被molin采纳,获得10
14秒前
15秒前
顺利毕业发布了新的文献求助10
15秒前
15秒前
16秒前
lxx发布了新的文献求助10
16秒前
笨笨松发布了新的文献求助10
16秒前
zty关闭了zty的文献求助
16秒前
可爱的函函的应助被so采纳,获得10
16秒前
我是谁的应助被jackson_WANG采纳,获得30
16秒前
17秒前
可恶地发布了新的文献求助10
18秒前
gzy发布了新的文献求助10
18秒前
lmy的应助被李瑞程采纳,获得10
18秒前
嘚哦完成签到,获得积分10
18秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Improving the wear resistance of vehicle gear oil by oil soluble LaF3 nanoparticles and typical additives of gear oil 500
Boundaries and Bodhisattvas 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8183324
求助须知:如何正确求助?哪些是违规求助? 9572627
关于积分的说明 21826529
捐赠科研通 7780320
什么是DOI,文献DOI怎么找? 3433993
关于科研通互助平台的介绍 2558155
邀请新用户注册赠送积分活动 2480290